chufangao/CTO huggingface dataset:
Clinical trial NCT03207256: Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
Official title: An Open Label Extension Trial of Ublituximab and/or Umbralisib (TGR-1202) in Combination With Other Novel Agents or as Single Agents in Subjects Currently Receiving Treatment on a TG Therapeutics Study.
Sponsor: TG Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Strategic/Business Decision
Enrollment: 51.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-09
Primary completion date: 2022-05-25
Completion date: 2022-06-24
Clinical trial NCT03803761: A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
Official title: A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination With Fulvestrant in Patients With Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Inadequate accrual rate
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-13
Primary completion date: 2022-02-19
Completion date: 2022-02-19
Plan to share individual participant data: YES
IPD sharing description: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Clinical trial NCT03170882: A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma
Official title: A Phase 2, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 122.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-01
Primary completion date: 2020-08-01
Completion date: 2021-11-26
Baseline population: Intent-to-Treat (ITT) Population included all participants who were randomized.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT01939691: Macular Edema Nepafenac vs. Difluprednate Uveitis Trial
Official title: Macular Edema Nepafenac vs. Difluprednate Uveitis Trial
Acronym: MEND
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Difficulty enrolling
Enrollment: 9.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-09-12
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Plan to share individual participant data: NO
Clinical trial NCT03754660: This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Official title: A Non-randomized Two Part Multi-center, Open-label, Single Dose Trial With an Escalation Part in Untreated Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Patients (Part A), Followed by a Parallel-group Part in Untreated and Pre-treated Patients With PAH and CTEPH (Part B) to Investigate the Safety, Tolerability and Pharmacodynamics of Inhaled BAY1237592
Acronym: ATMOS
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 38.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-01-21
Primary completion date: 2022-04-24
Completion date: 2022-11-03
Plan to share individual participant data: NO
IPD sharing description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access.~As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.~Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Clinical trial NCT01256359: Docetaxel With or Without AZD6244 in Melanoma
Official title: A Double Blind Randomised Phase 2 Trial of Docetaxel With or Without AZD6244 in wt BRAF Advanced Melanoma
Acronym: DOC-MEK
Sponsor: University of Oxford (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 83.0 (ACTUAL)
Number of arms: 2.0
Start date: 2010-10-31
Primary completion date: 2012-10-31
Completion date: 2020-02-29
Baseline population: All randomised patients
Clinical trial NCT04359823: DSAP Treatment Comparison: 2% Lovastatin/ 2% Cholesterol vs 2% Lovastatin Alone
Official title: Topical Treatment for Superficial Disseminated Actinic Porokeratosis: A Single-Blinded Comparison Between Lovastatin/Cholesterol and Lovastatin
Acronym: DSAP
Sponsor: Medical University of South Carolina (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 31.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-24
Primary completion date: 2021-04-23
Completion date: 2021-04-23
Limitations and caveats: Study was limited by covid pandemic requiring virtual appointments with participants. This prevented study team from acquiring in person dermoscopy data and overall limited physical exam assessments.
Plan to share individual participant data: NO
Clinical trial NCT03115801: A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
Official title: A Phase II Randomized Controlled Trial of Programmed Death -1/Programmed Death Ligand-1(PD-1/PDL-1) Axis Blockade Versus PD-1/PDL-1 Axis Blockade Plus Radiotherapy in Metastatic Genitourinary (Renal/Urothelial) Malignancies
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of accrual
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-11-30
Primary completion date: 2020-10-13
Completion date: 2020-10-13
Limitations and caveats: The clinical trial did not reach the target number of subjects needed to achieve target power and was insufficient to produce statistically reliable results.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04113616: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
Official title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
Sponsor: Kartos Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: In September 2023, the study was terminated because of a Sponsor decision, unrelated to safety concerns.
Enrollment: 70.0 (ACTUAL)
Number of arms: 6.0
Start date: 2019-09-25
Primary completion date: 2023-09-27
Completion date: 2023-09-27
Clinical trial NCT04864977: A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes
Official title: Novel Approach for Basal Insulin Titration: A Proof-of-Concept Study
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Study was stopped prior to study start date due to business decision.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-08-16
Primary completion date: 2022-06-06
Completion date: 2022-06-06
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT03376659: Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
Official title: A Phase I/II Trial of the PD-L1 Inhibitor, Durvalumab Plus CV301 in Combination With Maintenance Chemotherapy for Patients With Metastatic Colorectal or Pancreatic Adenocarcinoma
Sponsor: Georgetown University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study closed due to lack of enrollment.
Enrollment: 8.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-08-08
Primary completion date: 2021-08-30
Completion date: 2023-08-01
Plan to share individual participant data: NO
Clinical trial NCT04990388: Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)
Official title: A Phase 1/2 First-in-human, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses and Repeat Doses of UX053 in Patients With GSD III
Sponsor: Ultragenyx Pharmaceutical Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision not related to safety concerns
Enrollment: 9.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-10-18
Primary completion date: 2023-03-20
Completion date: 2023-03-20
Plan to share individual participant data: NO
Clinical trial NCT02282020: Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Official title: A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations.
Acronym: SOLO3
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 266.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-02-06
Primary completion date: 2018-10-10
Completion date: 2022-07-19
Baseline population: Baseline characteristics are displayed for all participants who started the study. This includes the 12 participants who did not receive treatment in the 'Single Agent Chemotherapy' arm.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.~All request will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT03958955: Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.
Official title: Efficacy and Safety of Twice-daily Application of Delgocitinib Cream 20 mg/g for 6 Weeks in Subjects With Active Discoid Lupus Erythematosus.
Sponsor: LEO Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Terminated due to recruitment challenges.
Enrollment: 27.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-09
Primary completion date: 2020-04-15
Completion date: 2020-04-30
Baseline population: Randomised subjects
Limitations and caveats: The trial was terminated prematurely due to slow recruitment, and due to an anticipation that recruitment would become further delayed due to the COVID-19 pandemic affecting recruitment activities. The total number of subjects included in the trial therefore ended with 27 subjects randomised. 26 subjects completed the trial, as 1 subject withdrew from the trial due to an AE (moderate cutaneous lupus erythematosus \[CLE\]; reported term: cutaneous lupus erythematosus flare).
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data (IPD) can be made available to researchers in a closed environment for a specified period of time.~Data sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement.
IPD time frame: Data is available to request after approval of the studied indication.
Clinical trial NCT04933942: Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma
Official title: Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-methylated Glioblastoma: a Randomized Phase II Open Label Multicenter Study
Acronym: RIGOLETTO
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Amgen withdrew interest in providing further financial support
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-09-13
Primary completion date: 2022-12-19
Completion date: 2022-12-19
Clinical trial NCT05104892: Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma
Official title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12 Week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of Rilzabrutinib in Participants With Moderate-to-severe Asthma Who Are Not Well Controlled on Inhaled Corticosteroid (ICS) Plus Long-acting β2 Adrenergic Agonist (LABA) Therapy
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 196.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-12
Primary completion date: 2024-02-06
Completion date: 2024-02-28
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT03883828: Bacterial Decolonization to Prevent Radiation Dermatitis
Official title: Bacterial Decolonization to Prevent Radiation Dermatitis: A Randomized Controlled Trial and Quality of Life Assessment
Sponsor: Montefiore Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 80.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-03
Primary completion date: 2021-12-02
Completion date: 2021-12-02
Baseline population: Baseline information and data was only collected for 77 participants (39 in the treatment arm and 38 in the control arm)
Plan to share individual participant data: NO
Clinical trial NCT05162131: Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PB2452 (Bentracimab) With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers
Sponsor: SFJ Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: After recruitment of Cohorts 1-4 was completed, Sponsor decided to terminate study, initially due to COVID and then considering that PK data from the dose planned to be tested in Cohort 5 (18000 mg) would be available from the ongoing Phase 3 study.
Enrollment: 34.0 (ACTUAL)
Number of arms: 7.0
Start date: 2021-12-25
Primary completion date: 2022-12-30
Completion date: 2022-12-30
Plan to share individual participant data: NO
Clinical trial NCT03679481: The Effect of Tranexamic Acid on Blood Loss and Transfusion Requirements Following Open Femur Fracture Surgery
Official title: The Effect of Tranexamic Acid on Blood Loss and Transfusion Requirements Following Open Femur Fracture Surgery
Sponsor: The University of Texas Health Science Center, Houston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: study not started due to lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-01
Primary completion date: 2021-04-01
Completion date: 2021-04-01
Clinical trial NCT04718467: Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)
Official title: A Single-center, Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅱb Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells), in the Subjects From Healthy Aged 18 to 85 Years Old
Sponsor: Jiangsu Province Centers for Disease Control and Prevention (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor decided to cancel this trial.
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-02-01
Primary completion date: 2021-05-15
Completion date: 2022-03-15
Clinical trial NCT03739866: Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults
Official title: A Phase 1b Randomized, Double-Blinded, Placebo Controlled, Multi-Cohort Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Subjects
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 53.0 (ACTUAL)
Number of arms: 8.0
Start date: 2018-11-26
Primary completion date: 2019-11-14
Completion date: 2020-06-15
Baseline population: Safety Analysis Set included all participants who were randomized/enrolled and received at least 1 dose of study drug.
Plan to share individual participant data: NO
Clinical trial NCT02795884: Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation
Sponsor: Yonsei University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Because of reconsideration of using erlotinib(EGFR Tyrosine kinase inhibitor) as adjuvant aim
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-30
Primary completion date: 2020-11-30
Completion date: 2020-11-30
Plan to share individual participant data: NO
IPD sharing description: no plan to share data
Clinical trial NCT03206970: Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Official title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 86.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-03-02
Primary completion date: 2019-02-15
Completion date: 2020-09-08
Baseline population: Safety Analysis Set: All participants who received any dose of study drug.
Plan to share individual participant data: YES
Clinical trial NCT03732807: PF-06651600 for the Treatment of Alopecia Areata
Official title: A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS
Acronym: ALLEGRO-2b/3
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 718.0 (ACTUAL)
Number of arms: 7.0
Start date: 2018-12-03
Primary completion date: 2020-12-31
Completion date: 2021-06-24
Baseline population: Full analysis set (FAS) included all participants who were randomized, regardless of whether they received study medication.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03680976: Anti-Inflammatory Lipid Mediators in Asthma
Official title: Anti-Inflammatory Lipid Mediators in Asthma
Acronym: ALMA
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The study will not take place at the University of Pittsburgh
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Primary completion date: 2021-04-30
Completion date: 2021-04-30
Clinical trial NCT04064684: Inhaled Steroids for the Treatment of Early Pediatric Acute Respiratory Distress Syndrome
Official title: Inhaled Steroids for the Treatment of Early Pediatric Acute Respiratory Distress Syndrome (PARDS), a Randomized Pilot Trial
Sponsor: The University of Texas Health Science Center, Houston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Enrollment difficulties after the start of the COVID-19 pandemic.
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-04
Primary completion date: 2020-03-30
Completion date: 2020-03-30
Limitations and caveats: Enrollment difficulties after start of the COVID-19 pandemic leading to small sample size
Plan to share individual participant data: NO